ライフサイエンスコーパス: cyclic adenosine monophosphate

1 edema toxin fails to increase intracellular cyclic adenosine monophosphate.

2 ays, as a phosphate donor or a precursor for cyclic adenosine monophosphate.

3 echanism acting through protein kinase A and cyclic adenosine monophosphate.

4 nhibits myelin gene activation by Krox-20 or cyclic adenosine monophosphate.

5 microscopy and intracellular accumulation of cyclic adenosine monophosphate.

6 ng an exchange protein directly activated by cyclic adenosine monophosphate 1 (EPAC1)-RAP1-dependent

7 The nucleotide signaling molecule 3',5'-cyclic adenosine monophosphate (3',5'-cAMP) plays import

8 utocrine stimulation of A2a receptors causes cyclic adenosine monophosphate accumulation at the back

9 The cystic fibrosis gene encodes a cyclic adenosine monophosphate-activated chloride channe

10 the supernatant and increased intracellular cyclic adenosine monophosphate activity.

11 ivating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (C

12 tor and is mediated via up-regulation of the cyclic adenosine monophosphate (AMP)/protein kinase A pa

13 Glucagon and a cyclic adenosine monophosphate analog increased promoter

14 Neither forskolin nor a membrane permeable cyclic adenosine monophosphate analog inhibited phosphor

15 activate its transcription in response to a cyclic adenosine monophosphate analog.

16 ained in culture and treated with either the cyclic adenosine monophosphate analogue 8-(4-chloropheny

17 es that regulate the intracellular levels of cyclic adenosine monophosphate and cyclic guanosine mono

18 A is an enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine mono

19 ndent signaling pathway that is dependent on cyclic adenosine monophosphate and extracellular signal-

20 ded in culture and decidualized with 8-bromo-cyclic adenosine monophosphate and medroxyprogesterone a

21 ffeine increases CcOX activity by increasing cyclic adenosine monophosphate and protein kinase A acti

22 oth cell types, as are forskolin, di-butyryl cyclic adenosine monophosphate, and adrenocorticotropin.

23 flagella, the second messengers calcium and cyclic adenosine monophosphate are implicated in modulat

24 In 3,5-cyclic adenosine monophosphate assays, the novel series

25 Strikingly, the measured on-rate for cyclic adenosine monophosphate binding is two orders of

26 Cyclic adenosine monophosphate binding not only unleashe

27 tions in ADCY5 was studied by measurement of cyclic adenosine monophosphate (cAMP) accumulation under

28 d by either a selective alpha2 antagonist, a cyclic adenosine monophosphate (cAMP) analogue, or an ad

29 s animal had an impaired capacity to degrade cyclic adenosine monophosphate (cAMP) and a blunted phar

30 Ucn1 is mediated initially by an increase in cyclic adenosine monophosphate (cAMP) and a subsequent i

31 Diminished cyclic adenosine monophosphate (cAMP) and augmented cycl

32 Interactions between cyclic adenosine monophosphate (cAMP) and Ca(2+) are wid

33 The cyclic adenosine monophosphate (cAMP) and Ca(2+) signali

34 Cytosolic cyclic adenosine monophosphate (cAMP) and cyclic guanosi

35 These second messengers include cyclic adenosine monophosphate (cAMP) and cyclic guanosi

36 Cyclic adenosine monophosphate (cAMP) and cyclic guanosi

37 he regulation of the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosi

38 lationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and m

39 Cyclic adenosine monophosphate (cAMP) and protein kinase

40 r1a (Prkar1a(+/-)), the primary receptor for cyclic adenosine monophosphate (cAMP) and regulator of p

41 This contributed to an increase in basal cyclic adenosine monophosphate (cAMP) and vasodilator-st

42 milar results were obtained with ISO-induced cyclic adenosine monophosphate (cAMP) as the outcome ind

43 In 3,5-cyclic adenosine monophosphate (cAMP) assays, the novel

44 In 3,5-cyclic adenosine monophosphate (cAMP) assays, the novel

45 behaved as a PTH1R antagonist in cell-based cyclic adenosine monophosphate (cAMP) assays, with selec

46 ion and prostaglandin E1-induced increase in cyclic adenosine monophosphate (cAMP) by ADP was impaire

47 Elevation of cyclic adenosine monophosphate (cAMP) can mimic axonal c

48 that in various model systems, elevation of cyclic adenosine monophosphate (cAMP) can potentiate glu

49 asic studies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major d

50 ype IV (PDE4), an important component of the cyclic adenosine monophosphate (cAMP) cascade, selective

51 A) R-subunit through formation of a PDE-PKAR-cyclic adenosine monophosphate (cAMP) complex (the termi

52 Cyclic adenosine monophosphate (cAMP) drives genetic pol

53 In Schwann cells (SCs), cyclic adenosine monophosphate (cAMP) enhances the actio

54 Elevation of cyclic adenosine monophosphate (cAMP) following cell det

55 Cyclic adenosine monophosphate (cAMP) has been implicate

56 Cyclic adenosine monophosphate (cAMP) has been intensive

57 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a p

58 ction by detecting naturally produced 3',5'- cyclic adenosine monophosphate (cAMP) in bacterial cultu

59 Tadalafil selectively increased cGMP but not cyclic adenosine monophosphate (cAMP) in brain.

60 sease is associated with increased levels of cyclic adenosine monophosphate (cAMP) in cholangiocytes

61 ing technology have revealed oscillations of cyclic adenosine monophosphate (cAMP) in insulin-secreti

62 the concentration of the secondary messenger cyclic adenosine monophosphate (cAMP) in MLT cells, in r

63 e we report a novel role for epinephrine and cyclic adenosine monophosphate (cAMP) in the regulation

64 reported to do so by only D1 receptor-driven cyclic adenosine monophosphate (cAMP) increases or D2 re

65 ieval from the canalicular membrane, whereas cyclic adenosine monophosphate (cAMP) increases plasma m

66 Cyclic adenosine monophosphate (cAMP) is a nearly ubiqui

67 Cyclic adenosine monophosphate (cAMP) is a negative regu

68 3',5'-Cyclic adenosine monophosphate (cAMP) is a pivotal secon

69 Cyclic adenosine monophosphate (cAMP) is a second messen

70 Cyclic adenosine monophosphate (cAMP) is an important me

71 Cyclic adenosine monophosphate (cAMP) is an important me

72 Cyclic adenosine monophosphate (cAMP) is generated by ad

73 Cyclic adenosine monophosphate (cAMP) is very important

74 While increased cyclic adenosine monophosphate (cAMP) levels are known t

75 E3A inhibitor, cilostazol, to modulate 3',5'-cyclic adenosine monophosphate (cAMP) levels in an in vi

76 in intrahepatic bile duct units (IBDUs) and cyclic adenosine monophosphate (cAMP) levels in cholangi

77 r (PLD) and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hep

78 Intracellular cyclic adenosine monophosphate (cAMP) levels tune the vo

79 In contrast, basal cyclic adenosine monophosphate (cAMP) levels, agonist-st

80 l methods such as elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, and depend

81 E17G increased cyclic adenosine monophosphate (cAMP) levels, and this i

82 tivation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate (cAMP) levels, which was

83 agonists that raise intracellular Ca(2+) or cyclic adenosine monophosphate (cAMP) levels.

84 r forskolin, both of which increase platelet cyclic adenosine monophosphate (cAMP) levels.

85 ive binding, Matrigel invasion and Galpha(i) cyclic adenosine monophosphate (cAMP) modulation signali

86 characterize the effects of these toxins and cyclic adenosine monophosphate (cAMP) on endosome ion tr

87 re, our genetic analyses have identified the cyclic adenosine monophosphate (cAMP) pathway and a prev

88 This study was designed to examine whether a cyclic adenosine monophosphate (cAMP) phosphodiesterase

89 Type 4 cyclic adenosine monophosphate (cAMP) phosphodiesterase

90 The second messenger cyclic adenosine monophosphate (cAMP) plays a pivotal ro

91 mary cultures of LMMP neurons (PC-LMMPn) and cyclic adenosine monophosphate (cAMP) production in huma

92 e aggregation and morphogenesis by secreting cyclic adenosine monophosphate (cAMP) pulses that propag

93 receptors (GPCRs) other than the four known cyclic adenosine monophosphate (cAMP) receptors (cAR1-4)

94 illations and elevation of 3'-5' [corrected] cyclic adenosine monophosphate (cAMP) reduced cellular p

95 Cyclic adenosine monophosphate (cAMP) regulates long-ter

96 The transcription factor cyclic adenosine monophosphate (cAMP) response element b

97 fferential cocaine-induced activation of the cyclic adenosine monophosphate (cAMP) response element b

98 nduction of nuclear transcription factors of cyclic adenosine monophosphate (cAMP) response element b

99 sly demonstrated that phosphorylation of the cyclic adenosine monophosphate (cAMP) response element-b

100 Second, we found that phosphorylation of cyclic adenosine monophosphate (cAMP) responsive-element

101 Kinase A (PKA) is the major receptor for the cyclic adenosine monophosphate (cAMP) secondary messenge

102 mitogen-activated protein kinase (MAPK) and cyclic adenosine monophosphate (cAMP) signal transductio

103 mitogen-activated protein kinase (MAPK) and cyclic adenosine monophosphate (cAMP) signal transductio

104 can generate spatial compartmentalization of cyclic adenosine monophosphate (cAMP) signaling at the c

105 per, we demonstrate a differential effect of cyclic adenosine monophosphate (cAMP) signaling between

106 DISC1 also regulates cyclic adenosine monophosphate (cAMP) signaling by incre

107 Using a marker of the cyclic adenosine monophosphate (cAMP) signaling cascade

108 We report here that cocaine and cyclic adenosine monophosphate (cAMP) signaling induce t

109 ickle cell disease and activated through the cyclic adenosine monophosphate (cAMP) signaling pathway.

110 Termination of cyclic adenosine monophosphate (cAMP) signaling via the

111 terase 3 (PDE3) is an important regulator of cyclic adenosine monophosphate (cAMP) signaling within t

112 to bile duct ligation (BDL) by activation of cyclic adenosine monophosphate (cAMP) signaling.

113 Cyclic adenosine monophosphate (cAMP) stimulates hepatic

114 Cyclic adenosine monophosphate (cAMP) stimulates translo

115 Here we show that glucagon and cyclic adenosine monophosphate (cAMP) strongly repressed

116 treatment increased intracellular levels of cyclic adenosine monophosphate (cAMP) that turned on pro

117 e-dependent increases in secondary-messenger cyclic adenosine monophosphate (cAMP) to activate protei

118 Binding of 3',5'-cyclic adenosine monophosphate (cAMP) to hyperpolarizati

119 receptor D1 (DRD1) via the second messenger cyclic adenosine monophosphate (cAMP) to synthetic promo

120 devices were treated with Angiopoietin 1 and cyclic adenosine monophosphate (cAMP) to vary the Pd of

121 In this study, we showed that cyclic adenosine monophosphate (cAMP) treatment induced

122 6A had a k(cat) of 0.235 s(-1), the K(m) for cyclic adenosine monophosphate (cAMP) was increased 11-f

123 Cyclic adenosine monophosphate (cAMP) was measured by ra

124 nsive controlled release of both insulin and cyclic adenosine monophosphate (cAMP) was synthesized.

125 Levels of cyclic adenosine monophosphate (cAMP) were elevated over

126 evels of phenylalanine, acetylhistidine, and cyclic adenosine monophosphate (cAMP) were found in urin

127 s) regulate the local concentration of 3',5' cyclic adenosine monophosphate (cAMP) within cells.

128 cell-permeable non-hydrolysable analogue of cyclic adenosine monophosphate (cAMP), 8-Br-cAMP.

129 Here we demonstrate that cyclic adenosine monophosphate (cAMP), a second messenge

130 Here we examine whether increases in cyclic adenosine monophosphate (cAMP), an intracellular

131 s of both a small molecule second messenger, cyclic adenosine monophosphate (cAMP), and a downstream

132 ially orchestrated by waves of extracellular cyclic adenosine monophosphate (cAMP), and previous theo

133 studies have implicated defective dopamine, cyclic adenosine monophosphate (cAMP), and Ras homeostas

134 gonist MRE-269 increased intracellular 3',5'-cyclic adenosine monophosphate (cAMP), augmented glucose

135 The second messenger, 3',5'-cyclic adenosine monophosphate (cAMP), is known to be mo

136 The cyclic adenosine monophosphate (cAMP), mitogen-activated

137 Dibutyryl cyclic adenosine monophosphate (cAMP), salmeterol, albut

138 with increased intracellular adenosine 3',5'-cyclic adenosine monophosphate (cAMP), the inhibition of

139 Cyclic adenosine monophosphate (cAMP), when added, induc

140 holoenzyme is one of the major receptors for cyclic adenosine monophosphate (cAMP), where an extracel

141 ith SCTR reduced ability of SCT to stimulate cyclic adenosine monophosphate (cAMP), with signaling au

142 en activated protein kinase (MAPK) and 3'-5'-cyclic adenosine monophosphate (cAMP)-associated signali

143 esynaptic function through activation of the cyclic adenosine monophosphate (cAMP)-cAMP-dependent pro

144 Here we studied the cyclic adenosine monophosphate (cAMP)-dependent gating i

145 Previously, we described a cyclic adenosine monophosphate (cAMP)-dependent increase

146 ht epithelial barrier can be up-regulated by cyclic adenosine monophosphate (cAMP)-dependent mechanis

147 almodulin-dependent kinase II (CaMKII) and a cyclic adenosine monophosphate (cAMP)-dependent pathway.

148 In its physiological state, cyclic adenosine monophosphate (cAMP)-dependent protein

149 2(+)(i))-dependent protein kinase C (PKC) or cyclic adenosine monophosphate (cAMP)-dependent protein

150 Furthermore, we demonstrated that Tregs use cyclic adenosine monophosphate (cAMP)-dependent protein

151 The catalytic (C) subunit of cyclic adenosine monophosphate (cAMP)-dependent protein

152 involved in the natural association between cyclic adenosine monophosphate (cAMP)-dependent protein

153 The 2.0-angstrom structure of the cyclic adenosine monophosphate (cAMP)-dependent protein

154 ow found that up-regulation of intracellular cyclic adenosine monophosphate (cAMP)-dependent protein

155 lates repulsive axon guidance by linking the cyclic adenosine monophosphate (cAMP)-dependent protein

156 t experiments examined whether inhibition of cyclic adenosine monophosphate (cAMP)-dependent protein

157 nmination task and the activity profiles for cyclic adenosine monophosphate (cAMP)-dependent protein

158 )-releasing activities was demonstrated with cyclic adenosine monophosphate (cAMP)-dependent protein

159 tight spatiotemporal signaling control, the cyclic adenosine monophosphate (cAMP)-dependent protein

160 sed approach was applied to the prototypical cyclic adenosine monophosphate (cAMP)-dependent protein

161 Met) encoding the gamma-catalytic subunit of cyclic adenosine monophosphate (cAMP)-dependent protein

162 Cyclic adenosine monophosphate (cAMP)-dependent signalin

163 Cyclic adenosine monophosphate (cAMP)-dependent signalin

164 dian rhythms of LC opsin mRNA expression via cyclic adenosine monophosphate (cAMP)-dependent signalin

165 A cocktail of cyclic adenosine monophosphate (cAMP)-elevating agents p

166 -1, promotes beta cell Tcf7 expression via a cyclic adenosine monophosphate (cAMP)-independent and ex

167 n of the aryl hydrocarbon receptor (AhR) and cyclic adenosine monophosphate (cAMP)-mediated signaling

168 regulation of NMJ growth occurs through the cyclic adenosine monophosphate (cAMP)-protein kinase A (

169 e somatodendritic domain, depends on ongoing cyclic adenosine monophosphate (cAMP)-protein kinase A (

170 d stimulation of the prostaglandin E2 (PGE2)-cyclic adenosine monophosphate (cAMP)-protein kinase A (

171 omains and an ERM binding site to coordinate cyclic adenosine monophosphate (cAMP)-regulated ion tran

172 -kappaB), activator of protein-1 (AP-1), and cyclic adenosine monophosphate (cAMP)-responsive element

173 nd that genetic deletion of HCN2 removed the cyclic adenosine monophosphate (cAMP)-sensitive componen

174 sults from Cl(-)/HCO(3)(-) exchange, whereas cyclic adenosine monophosphate (cAMP)-stimulated secreti

175 reported including increased levels of 3'-5'-cyclic adenosine monophosphate (cAMP).

176 causes a dramatic increase of intracellular cyclic adenosine monophosphate (cAMP).

177 e and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP).

178 egulating production of the second messenger cyclic adenosine monophosphate (cAMP).

179 of the intracellular second messenger 3',5'-cyclic adenosine monophosphate (cAMP).

180 le-cell chemotaxis towards emitted pulses of cyclic adenosine monophosphate (cAMP).

181 entration gradient of the signaling molecule cyclic adenosine monophosphate (cAMP).

182 r(s) and an intrinsic platelet mechanism via cyclic adenosine monophosphate (cAMP)/adenylate cyclase,

183 of large cholangiocytes is regulated by the cyclic adenosine monophosphate (cAMP)/extracellular sign

184 In polycystin-2 (PC2)-defective mice, cyclic adenosine monophosphate (cAMP)/protein kinase A (

185 poly(ADP-ribose) polymerase 1 (PARP1) by the cyclic adenosine monophosphate (cAMP)/protein kinase A (

186 l cells by beta-adrenergic signaling through cyclic adenosine monophosphate (cAMP); however, the mech

187 ere identified as full antagonist ligands on cyclic adenosine monophosphate (cAMP, KB = 4.9 and 5.9 n

188 sterone release as well as adrenal levels of cyclic adenosine monophosphate (cAMP, the second messeng

189 responsible for extAdo-triggered signaling (cyclic adenosine monophosphate [cAMP] accumulation) in m

190 ed signaling pathway function (Ras activity, cyclic adenosine monophosphate [cAMP], and dopamine leve

191 e.g., glutamatergic, monoaminergic, calcium, cyclic adenosine monophosphate [cAMP], dopamine- and cAM

192 s phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-

193 Coactivators p300 and CREB (cyclic adenosine monophosphate [cAMP]-response element b

194 ns and is regulated by opposing stimulatory (cyclic adenosine monophosphate, cAMP) and inhibitory (in

195 in zebrafish that post-injury application of cyclic adenosine monophosphate can transform severed CNS

196 (1 microm) markedly increased intracellular cyclic adenosine monophosphate concentrations but did no

197 roterenol-induced increases in intracellular cyclic adenosine monophosphate concentrations but did no

198 m, did not measurably increase intracellular cyclic adenosine monophosphate concentrations yet inhibi

199 Adenosine, xanthine, hypoxanthine, and cyclic-adenosine monophosphate correlated with lactate o

200 odiesterase 10A (PDE10A), a dual-specificity cyclic adenosine monophosphate/cyclic guanosine monophos

201 h repeat kinase 2 was inhibited by dibutyryl-cyclic adenosine monophosphate, cytoplasmic expression o

202 homologous to the dimerization interface of cyclic adenosine monophosphate dependent PKA RII-alpha,

203 conditions that trigger the damage of large cyclic adenosine monophosphate-dependent cholangiocytes.

204 ; cyclic adenosine monophosphate levels; and cyclic adenosine monophosphate-dependent protein kinase

205 A) of the type I regulatory subunit alpha of cyclic adenosine monophosphate-dependent protein kinase

206 etagamma, G protein-coupled receptor kinase, cyclic adenosine monophosphate-dependent protein kinase,

207 a mitogen-activated protein kinase cascade, cyclic adenosine monophosphate-dependent protein kinase,

208 contained a G protein, an adenylyl cyclase, cyclic adenosine monophosphate-dependent protein kinase,

209 encoding the gamma-catalytic subunit of the cyclic adenosine monophosphate-dependent protein kinase,

210 PDGF-BB induced cyclic adenosine monophosphate-dependent protein kinase-

211 the activation of neuronal EP2 receptors and cyclic adenosine monophosphate-dependent protein kinase.

212 y phosphorylation of its headpiece domain by cyclic adenosine monophosphate-dependent protein kinase.

213 Optogenetic upregulation of cyclic adenosine monophosphate during the day increases

214 AVP/cyclic adenosine monophosphate enhance the phosphorylati

215 of adenylyl cyclase (AC) and an increase in cyclic adenosine monophosphate formation.

216 the ion channel hyperpolarization-activated cyclic adenosine monophosphate gated channel type 1 (HCN

217 AC(VI), unlike other strategies to increase cyclic adenosine monophosphate generation, reduces morta

218 on restores the suppressive effects of 3',5'-cyclic adenosine monophosphate in lymphocytes.

219 ogen-activated protein kinase signaling in a cyclic adenosine monophosphate-independent manner.

220 al potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcar

221 Cyclic adenosine monophosphate-induced enteroid intracel

222 C(IR800)-TOC demonstrated higher potency for cyclic adenosine monophosphate inhibition (half maximal

223 lus epithelium is required for intracellular cyclic adenosine monophosphate inhibition of Na(+)/H(+)

224 rotein (GP)IIb/IIIa activation and decreased cyclic adenosine monophosphate levels (n = 6, P < .01) i

225 occur in concert with an attenuated rise in cyclic adenosine monophosphate levels in response to pro

226 EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis a

227 elease of neurotrophins together with raised cyclic adenosine monophosphate levels in treated culture

228 ung airway reactivity by modulating the lung cyclic adenosine monophosphate levels through changes in

229 VILIP-1 enhances cyclic adenosine monophosphate levels through PKA induct

230 g but was causally related to decreased lung cyclic adenosine monophosphate levels, increased phospho

231 t significantly alter airway responsiveness, cyclic adenosine monophosphate levels, or the phosphodie

232 ystolic function without changing myocardial cyclic adenosine monophosphate levels.

233 pression of the cardiac stress marker NR4A1; cyclic adenosine monophosphate levels; and cyclic adenos

234 herapy with NgR(310)ecto-Fc plus rolipram, a cyclic adenosine monophosphate phosphodiesterase inhibit

235 (mitogen-activated protein kinase) and cAMP (cyclic adenosine monophosphate)-PKA (protein kinase A) c

236 ated that rolipram, an anti-inflammatory and cyclic adenosine monophosphate preserving small molecule

237 nal antagonist that inhibited CRF-stimulated cyclic adenosine monophosphate production and CRF-induce

238 sponse (UPR), intracellular ion homeostasis, cyclic adenosine monophosphate production and regulation

239 on, adenosine uptake by red blood cells, and cyclic adenosine monophosphate production by cells overe

240 and osteoclast differentiation by enhancing cyclic adenosine monophosphate production through an uni

241 on, while augmenting beta-agonist-stimulated cyclic adenosine monophosphate production.

242 estins also augments beta-agonist-stimulated cyclic adenosine monophosphate production.

243 exocytic events were mediated, in part, by a cyclic adenosine monophosphate, protein kinase A-depende

244 cholangiocytes show increased production of cyclic adenosine monophosphate, protein kinase A-depende

245 that loss of actin stress fibers is due to a cyclic adenosine monophosphate, protein kinase A-mediate

246 echanism of ICAM-4 activation occurs via the cyclic adenosine monophosphate-protein kinase A (cAMP-PK

247 de monotherapy, which elevates intracellular cyclic adenosine monophosphate/protein kinase A (cAMP-PK

248 d prostacyclin which stimulates the platelet cyclic adenosine monophosphate/protein kinase A (cAMP/PK

249 Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway

250 g Western blot analysis, Oil-Red-O staining, cyclic adenosine monophosphate radioimmunoassay, immunof

251 estigated the role of DARPP-32 (dopamine and cyclic adenosine monophosphate-regulated phosphoprotein,

252 als that PGE(2) signal to HPK1 via a 3' -5 '-cyclic adenosine monophosphate-regulated, PKA-dependent

253 Cyclic adenosine monophosphate relaxes airway smooth mus

254 clear fractions by means of Western blot and cyclic adenosine monophosphate response element (CRE)-DN

255 nscriptional activity and phosphorylation of cyclic adenosine monophosphate response element binding

256 increases the levels of transcription factor cyclic adenosine monophosphate response element binding

257 running on the phosphorylation of Akt, AMPK, cyclic adenosine monophosphate response element binding

258 Cyclic adenosine monophosphate response element binding

259 -like factor 1 (ELF-1; between -49 and -52), cyclic adenosine monophosphate response element binding

260 A polymorphism near the cyclic adenosine monophosphate response element binding

261 Because cyclic adenosine monophosphate response element binding

262 These neurons also showed persistent cyclic adenosine monophosphate response element binding

263 ated protein kinase p42/p44 (MAPK(p42/p44)), cyclic adenosine monophosphate response element binding

264 Cyclic adenosine monophosphate response element binding

265 nvestigated the functional regulation of the cyclic adenosine monophosphate response element binding

266 whereas expression of the binding protein of cyclic adenosine monophosphate response element binding

267 have shown that nuclear transcription factor cyclic adenosine monophosphate response element binding

268 d neurotrophic factor and phosphorylation of cyclic adenosine monophosphate response element binding

269 glycosylation of the transducer of regulated cyclic adenosine monophosphate response element-binding

270 activation and is required for signaling to cyclic adenosine monophosphate response element-binding

271 promoter regions of the transcription factor cyclic adenosine monophosphate response element-binding

272 wn of DISC1 caused a significant increase of cyclic adenosine monophosphate response element-binding

273 roximal promoter region as well as increased cyclic adenosine monophosphate response element-mediated

274 Cyclic adenosine monophosphate response-element binding

275 hancer binding protein-beta (C/EBPbeta), and cyclic adenosine monophosphate-response element binding

276 Here we identify cyclic adenosine monophosphate responsive element bindin

277 /ERK), leading to down-regulation of phospho-cyclic adenosine monophosphate responsive element-bindin

278 scription factor that is a member of the ATF/cyclic adenosine monophosphate responsive element-bindin

279 The transcription factor, cyclic adenosine monophosphate-responsive element modula

280 ation-transcription coupling caused by CREB (cyclic adenosine monophosphate-responsive element-bindin

281 Stimulation of intracellular cyclic adenosine monophosphate resulted in cessation of

282 eptor was found to be functionally active in cyclic adenosine monophosphate signal assays.

283 Thus, CARM1 functions as a corepressor in cyclic adenosine monophosphate signaling pathway via its

284 The current study examined whether D1R-cyclic adenosine monophosphate signaling reduces neurona

285 of dopamine D1 receptor (D1R) activation of cyclic adenosine monophosphate signaling, which reduces

286 he effects of dopamine receptor D2 (DRD2) on cyclic adenosine monophosphate signaling; PDAC tissues h

287 REB, CRE-DNA binding activity, and basal and cyclic adenosine monophosphate-stimulated protein kinase

288 ion, we determined the catalytic activity of cyclic adenosine monophosphate-stimulated protein kinase

289 cell volume were unaffected by intracellular cyclic adenosine monophosphate stimulation in NKCC1(-) j

290 es in CFTR(-) epithelium after intracellular cyclic adenosine monophosphate stimulation.

291 -mediated generation of the second messenger cyclic adenosine monophosphate, suggesting that alterati

292 Rap-1 is also activated directly by cyclic adenosine monophosphate through Epac, and thus pa

293 phodiesterase type 4 inhibitor and dibutyryl cyclic adenosine monophosphate to overcome myelin-mediat

294 A well-studied system is the binding of cyclic adenosine monophosphate to the cyclic nucleotide

295 Newly synthesized 32P-cyclic adenosine monophosphate was isolated by sequentia

296 transient loss of worm motility dependent on cyclic adenosine monophosphate, whereas transient photoa

297 ctor 3/exchange factor directly activated by cyclic adenosine monophosphate, which maintains vascular

298 Increases in cyclic adenosine monophosphate with forskolin caused ent

299 not respond to stimulation of intracellular cyclic adenosine monophosphate with inhibition of electr

300 O, guanosine 3',5'-cyclic monophosphate, and cyclic adenosine monophosphate with reduced spreading on